Research statistics

Petrelintide research: publications and trials

What has been published on Petrelintide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Petrelintide works or is safe. For what it is and what the studies found, see the Petrelintide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

8

Since 2025

Publications in 2026 so far

6

Through November 15, 2026

Human clinical research

25.0%

2 of 8 classified

Registered clinical trials

12

ClinicalTrials.gov

Randomized controlled trials

2

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

25.0%

1 animal · 1 in vitro · 0 computational

Records that only mention it

1

Not counted above

Status in the library: In clinical trials. Groups: Amylin analogues.

What to keep in mind

  • Fewer than three randomized controlled trials are indexed.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Petrelintide publications by year and evidence

2025, Preclinical (animal, in vitro, computational): 2 of 22026 (to date), Human clinical research: 2 of 62026 (to date), Reviews and meta-analyses: 3 of 62026 (to date), Other and not yet classified: 1 of 6Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified024620252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202502002
2026 (to date)20316

Study types

Review3
Randomized controlled trial2
Animal study1
In vitro study1
Editorial, letter or other1

Research areas

From MeSH major topics. A paper can be in several areas.

Obesity and weight management6
Metabolic health3
Endocrinology1

Registered clinical trials

2 of 3 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 6 · Recruiting: 5 · Not yet recruiting: 1
Phase 1: 5 · Phase 2: 4 · Phase 3: 3

TrialStatusPhaseStartedResults
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686 · 486 enrolledNot yet recruitingPhase 22026-11—
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesNCT07843485 · 600 enrolledRecruitingPhase 32026-10—
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular DiseaseNCT07843472 · 2,500 enrolledRecruitingPhase 32026-09—
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or ObesityNCT07843498 · 3,900 enrolledRecruitingPhase 32026-09—
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionNCT07682818 · 36 enrolledRecruitingPhase 12026-05—
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsNCT07338214 · 48 enrolledCompletedPhase 12025-12—
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · 221 enrolledCompletedPhase 22025-04—
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal FunctionNCT07076030 · 39 enrolledCompletedPhase 12025-04—
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum DisorderNCT06951854 · 105 enrolledRecruitingPhase 22025-04—
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesNCT06662539 · 493 enrolledCompletedPhase 22024-12—
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy ParticipantsNCT05613387 · 68 enrolledCompletedPhase 12022-11—
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial ParticipantsNCT05096598 · 64 enrolledCompletedPhase 12021-10—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.

    The lancet. Diabetes & endocrinology · September 29, 2026 · Randomized controlled trial · cited 0 times

    PMID 42810355 · DOI 10.1016/s2213-8587(26)00213-5 · Human clinical research

  2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

    Diabetes, obesity & metabolism · April 22, 2026 · Randomized controlled trial · cited 3 times · open access

    PMID 42017294 · DOI 10.1111/dom.70753 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.

    Journal of medicinal chemistry · November 11, 2025 · Animal study · cited 14 times · open access

    PMID 41217931 · DOI 10.1021/acs.jmedchem.5c01185 · Animal studies

  2. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.

    Journal of medicinal chemistry · July 3, 2025 · In vitro study · cited 8 times

    PMID 40608546 · DOI 10.1021/acs.jmedchem.5c01120 · In vitro studies

  3. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

    Peptides · February 24, 2026 · Review · cited 6 times · open access

    PMID 41747885 · DOI 10.1016/j.peptides.2026.171480 · Reviews and meta-analyses

  4. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

    Diabetes, obesity & metabolism · April 22, 2026 · Randomized controlled trial · cited 3 times · open access

    PMID 42017294 · DOI 10.1111/dom.70753 · Human clinical research

  5. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.

    Diabetes, obesity & metabolism · July 14, 2026 · Review · cited 1 times · open access

    PMID 42452898 · DOI 10.1111/dom.71074 · Reviews and meta-analyses

Latest publications

  1. Petrelintide and the evolving role of amylin agonism in obesity.

    The lancet. Diabetes & endocrinology · September 29, 2026 · Editorial, letter or other · cited 0 times

    PMID 42810353 · DOI 10.1016/s2213-8587(26)00216-0 · Commentary and other

  2. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.

    The lancet. Diabetes & endocrinology · September 29, 2026 · Randomized controlled trial · cited 0 times

    PMID 42810355 · DOI 10.1016/s2213-8587(26)00213-5 · Human clinical research

  3. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.

    Pharmacological research · August 12, 2026 · Review · cited 0 times · open access

    PMID 42586227 · DOI 10.1016/j.phrs.2026.108382 · Reviews and meta-analyses

  4. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.

    Diabetes, obesity & metabolism · July 14, 2026 · Review · cited 1 times · open access

    PMID 42452898 · DOI 10.1111/dom.71074 · Reviews and meta-analyses

  5. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

    Diabetes, obesity & metabolism · April 22, 2026 · Randomized controlled trial · cited 3 times · open access

    PMID 42017294 · DOI 10.1111/dom.70753 · Human clinical research

  6. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

    Peptides · February 24, 2026 · Review · cited 6 times · open access

    PMID 41747885 · DOI 10.1016/j.peptides.2026.171480 · Reviews and meta-analyses

  7. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.

    Journal of medicinal chemistry · November 11, 2025 · Animal study · cited 14 times · open access

    PMID 41217931 · DOI 10.1021/acs.jmedchem.5c01185 · Animal studies

  8. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.

    Journal of medicinal chemistry · July 3, 2025 · In vitro study · cited 8 times

    PMID 40608546 · DOI 10.1021/acs.jmedchem.5c01120 · In vitro studies

Browse all 8 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Petrelintide; ZP8396

((TITLE_ABS:"Petrelintide" OR CHEM:"Petrelintide") OR (TITLE_ABS:"ZP8396" OR CHEM:"ZP8396" OR TITLE_ABS:"ZP 8396" OR CHEM:"ZP 8396")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Petrelintide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/petrelintide